window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 12, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

clinical remission

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Amorphical reports positive long-term Phase 2 results for Crohn’s disease therapy

    Amorphical has announced positive final long-term results from its Phase [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Amorphical reports positive interim results from ongoing Crohn’s disease trial

    Amorphical, developer of nano-amorphous mineral-based pharmacologic agents, has announced positive [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Opinion & Events

    NICE backs mirikizumab for treatment-resistant Crohn’s disease

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Trelleborg gains ISO certification for Costa Rica medtech plant
    Categories: Clinical & Regulatory, Manufacturing & Supply Chain, Medical devices
  • Merck launches bio-based HPLC solvents for pharma labs
    Categories: Drug Discovery & Development, Manufacturing & Supply Chain
  • Alto starts Phase 2b ALTO-207 trial in treatment-resistant depression
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top